Comparison of the Effects of Hexavalent Chromium in the Alimentary Canal of F344 Rats and B6C3F1 Mice Following Exposure in Drinking Water: Implications for Carcinogenic Modes of Action by Thompson, Chad M. et al.
TOXICOLOGICAL SCIENCES 125(1), 79–90 (2012)
doi:10.1093/toxsci/kfr280
Advance Access publication October 19, 2011
Comparison of the Effects of Hexavalent Chromium in the Alimentary
Canal of F344 Rats and B6C3F1 Mice Following Exposure in Drinking
Water: Implications for Carcinogenic Modes of Action
Chad M. Thompson,*
,1 Deborah M. Proctor,† Mina Suh,† Laurie C. Haws,‡ Charles D. He ´bert,§ Jill F. Mann,§
Howard G. Shertzer,{ J. Gregory Hixon,‡ and Mark A. Harris*
*ToxStrategies, Inc., Katy, Texas 77494; †ToxStrategies, Inc., Rancho Santa Margarita, California 92688; ‡ToxStrategies, Inc., Austin,
Texas 78731; §Southern Research Institute, Birmingham, Alabama 35205; and {Department of Environmental Health,
University of Cincinnati College of Medicine, Cincinnati, Ohio 45267
1To whom correspondence should be addressed at ToxStrategies, Inc., 23501 Cinco Ranch Boulevard, Suite G265, Katy, TX 77494. Fax: (832) 218-2756.
E-mail: cthompson@toxstrategies.com.
Received August 22, 2011; accepted October 10, 2011
Exposure to high concentrations of hexavalent chromium (Cr[VI])
in drinking water is reported to induce oral mucosa tumors in F344
rats and intestinal tumors in B6C3F1 mice. To investigate the modes
of action underlying these tumors, 90-day drinking water studies
(with interim necropsy at day 8) were conducted with concentrations
of 0.1–182 mg/l Cr(VI), administered as 0.3–520 mg/l sodium
dichromate dihydrate. Blood and tissue samples were analyzed for
chromium content, oxidative stress, iron levels, and gross and
microscopic lesions. Results for the F344 rats are described herein
and compared with results from B6C3F1 mice published previously.
After 90 days of exposure, total chromium concentrations in the rat
and mouse oral mucosae were comparable, yet signiﬁcant dose-
dependent decreases in the reduced-to-oxidized glutathione ratio
(GSH/GSSG) were observed only in rats. In the duodenum, changes
in GSH/GSSG were only observed in mice. Levels of 8-hydrox-
ydeoxyguanosine were not increased in the oral or duodenal
mucosae of either species. Glutathione levels were increased in the
duodenum but decreased in the jejunum of both species, indicating
potential differential responses in the intestinal segments. Histiocytic
inﬁltration was observed in the duodenum of both species, yet
duodenal cytokines were repressed in mice but increased in rats.
Serum and bone marrow iron levels were more decreased in rats
than mice. Collectively, these data suggest that Cr(VI)-induced
carcinogenesis in the rodent alimentary canal involves oxidative
stress; however, differences in histopathology, cytokines, and iron
status suggest potential contributions from other factors as well.
Key Words: drinking water; oxidative stress; carcinogenesis;
Cr(VI); MOA.
Chronic ingestion of hexavalent chromium (Cr(VI)), in the
form of sodium dichromate dihydrate (Na2Cr2O7
d2H2Oo r
SDD), in drinking water has been found to induce oral mucosa
tumors in rats at concentrations   172 mg SDD/l, and intestinal
tumors in mice at concentrations   57.3 mg SDD/l (National
Toxicology Program [NTP], 2008; Stout et al., 2009). Villous
cytotoxicity and crypt hyperplasia were observed in the mouse
small intestine, whereas no obvious non-neoplastic lesions
were observed in the oral mucosae of rats (NTP, 2008; Stout
et al., 2009). The different lesions suggest that the tumors in
the two sites may have arisen through different carcinogenic
modes of action (MOAs). Although the NTP (2008) 2-year
bioassay demonstrated that Cr(VI) was carcinogenic in rodents
following chronic exposure to high concentrations in drinking
water, the study did not provide adequate data for un-
derstanding how the tumors arose or why different tumors
were observed in each species. Because mice and rats
developed tumors in different tissues of the alimentary canal,
comparisons of species-speciﬁc pathology and biochemistry in
the target tissues (i.e., oral and intestinal mucosae) are expected
to inform the MOAs for carcinogenicity in each tissue.
Several authors have proposed or discussed possible MOAs
for alimentary cancers in rodents (McCarroll et al., 2010; Stern,
2010; Thompson et al., 2011a). However, currently available
data are insufﬁcient to conclusively support any of the
hypothesized MOAs. This is especially true for oral squamous
cell carcinomas originating from the rat palate after 2 years of
exposure to SDD, where no non-neoplastic lesions were
reported (NTP, 2007, 2008; Stout et al., 2009). The number of
oral cavity tumors was signiﬁcantly elevated as compared to
current and historical controls in the highest dose group (516
mg/l) in both males (6/49) and females (11/50), as well as
historical controls in females in the 172 mg/l treatment group
(2/50) (NTP, 2008; Stout et al., 2009). Stout et al. (2009) noted
that 21 chemicals have been shown to cause oral cavity tumors
in rats, but no chemicals have been shown to cause oral cavity
tumors in male mice, and only one caused oral cavity tumors in
female mice. These ﬁndings may suggest an inherent
susceptibility of rats to oral cancers.
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dependent decrease in mean red blood cell (RBC) volume,
mean cell hemoglobin (Hb) and hematocrit, indicating
microcytic hypochromic anemia (NTP, 2008). Earlier studies
reported similar anemic effects in rats exposed to Cr(VI),
regardless of whether administered in feed or water (NTP,
1996, 1997, 2007). Although anemic effects were also
observed in mice in the NTP (2008) study, effects in mice
were milder. Interestingly, one study has shown that anemia
can increase the risk of oral cancer in rats (Prime et al., 1983);
thus, it is conceivable that the anemic effects in rats play a role
in the MOA of the oral tumors.
To better understand the MOAs for the alimentary cancers
observed in the NTP 2-year bioassay (NTP, 2008), Thompson
et al. (2011a) conducted a comprehensive review of available
literature to develop a plausible MOA for the intestinal tumors
in mice, identiﬁed key data gaps in that MOA, and designed
a 90-day drinking water study to address those data gaps.
Although a formal MOA analysis was not conducted for the
oral cavity tumors observed in rats, data necessary to evaluate
possible key events in the MOAs were collected from the target
tissues of both species. These biochemical, toxicogenomic, and
toxicokinetic data should inform the MOAs for Cr(VI) in the
mouse intestine as well as in the rat oral mucosa. For the
reasons described above, endpoints related to tissue and serum
iron levels were collected. The overall study design is
summarized in Table 1 and is similar to that of the 90-day
NTP study (NTP, 2007). Herein we report results from the 90-
day rat study including descriptions of the histopathological
ﬁndings, biochemical analyses related to oxidative status, and
the chromium content in target tissues. Moreover, these results
are compared with those previously reported for mice
(Thompson et al., 2011b) to provide additional insight into
key events in the MOAs. These data will provide phenotypic
anchoring for future toxicogenomic results, which will be
published separately upon completion.
MATERIALS AND METHODS
Test substance. SDD (CAS 7789-12-0) (99.95% pure) was obtained from
Sigma-Aldrich, Inc. (Milwaukee, WI) and stored at room temperature and
protected from light. The dose formulations were prepared at concentrations of
0.3, 4, 60, 170, and 520 mg/l SDD in tap water, which is equivalent to 0.1, 1.4,
4.9, 20.9, 59.3, and 181 mg/l Cr(VI) (the Cr(VI) concentration is equivalent to
~35% of the SDD concentration). On the ﬁrst, third, ﬁfth, and seventh (ﬁnal)
batch preparations, samples of formulations for each dose group, including the
control, were collected and shipped to Brooks Rand Laboratories (Seattle, WA)
for analysis of Cr(VI) content. The ﬁrst batch was also analyzed for total
chromium. Samples were prepared and analyzed in accordance with EPA
Method SW-7196A to conﬁrm the Cr(VI) concentrations of the administered
drinking water. In Method 7196A, Cr(VI) is complexed with diphenylcarbazide
in an acidic solution and absorbance is measured at 540 nm. Batches found to
differ from the target concentration by ±10% were not used. Prior to use, dose
formulations of SDD were stored in sealed Nalgene carboys at room
temperature protected from light, which has been shown to be stable for 42
days in dosed water formulations at a concentration of 41.8 mg/l when stored
under these conditions (NTP, 2008).
Animals and husbandry. The in-life portion of the study was conducted
at Southern Research Institute (Birmingham, AL), the same research facility
that conducted both the NTP 13-week and 2-year bioassays (NTP, 2007,
2008). The same strain of female rats (Fischer 344/N) was used in the current
study as in the NTP studies. Rats in the current study were obtained from
Charles River Laboratories International, Inc. (Stone Ridge, NY), whereas the
rats in the NTP studies were obtained from Taconic Farms (Germantown,
NY). The rats were ~4 weeks of age when they arrived and were allowed to
acclimate for ~2 weeks. At the start of the study, the rats weighed between
83.1 and 126.4 g. Animals were allowed ad libitum access to the same chow as
in the NTP studies, namely, irradiated NTP-2000 Wafers (Zeigler Bros.,
Gardners, PA). Water (dosed or control) was supplied in amber glass water
bottles. Teﬂon-lined lids with stainless steel, double-balled sipper tubes were
used. Water bottles were changed twice weekly or as needed. Analysis of tap
water from the animal facility prior to the study indicated that no contaminants
TABLE 1
Treatment Groups
Number of female F344 rats
A
a BC D E
Toxicology and histopathology Biochemical evaluations Gene expression analysis Mutation analysis Toxicokinetic analyses
SDD (mg/l) Day 8 Day 91 Day 8 Day 91 Day 8 Day 91 Day 91 Day 91
0 5 10 10 15 10 10 10 5
0.3 5 10 10 15 10 10 10 5
4 5 10 10 15 10 10 10 5
60 5 10 10 15 10 10 10 5
170 5 10 10 15 10 10 10 5
520 5 10 10 15 10 10 10 5
aCohort subgroups for assays.
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the study.
Rats were group-housed (ﬁve per cage) in solid bottom, polycarbonate
cages on a stainless steel rack in a room maintained at a temperature of
60.7 F–84.1 F and relative humidity of 28.4–100%. Excursions outside the
desired temperature (69 F–75 F) and humidity (35–65%) ranges were brief
in duration and did not adversely affect the health of the animals or
outcome of the study. Fluorescent lighting provided illumination ~12 h/
day. Irradiated hardwood bedding chips (Sani-Chips; P.J. Murphy Forest
Products Corp., Montville, NJ) were used as bedding material. No known
contaminants were present in the bedding that would have been expected to
interfere with or affect the outcome of the study. Cage size and animal care
c o n f o r m e dt ot h eGuide for the Care and Use of Laboratory Animals,t h e
U.S. Department of Agriculture through the Animal Welfare Act (Public
Law 99-198), and to the applicable Standard Operating Procedures of
Southern Research Institute.
Study design. Male and female F344 rats responded similarly to Cr(VI) in
the previous 2-year bioassay (NTP, 2008); therefore, only female rats were used
in this present study. Animals were assigned to treatment groups as indicated in
Table 1 and were provided with food and drinking water ad libitum until study
termination at days 8 or 91 (Table 1). Water and food consumption were
measured weekly for each cage of animals throughout the study, and values
were reported as an average daily consumption (milliliters/animal or grams/
animal, respectively). During treatment, animals were weighed on day 1,
weekly thereafter, and prior to scheduled euthanasia. All animals were observed
at least twice daily during the prestudy and study periods for signs of mortality
and moribundity. Each animal was removed from its cage and examined for
clinical signs of toxicity (e.g., alopecia, eye discharge, piloerection,
hyperexcitability) on day 1 and weekly thereafter.
Pathology and histopathology. Pathology and histopathology were
assessed in ﬁve animals from each treatment group on day 8 and 10 animals
per treatment group on day 91 (subgroup A, Table 1). The animals were
euthanized by CO2 asphyxiation and subjected to a postmortem examination
that included, but was not limited to, examination of the external surfaces of the
body, all oriﬁces of the body, and the cranial, thoracic, abdominal, and pelvic
cavities and their contents. Based on ﬁndings of the NTP 2-year bioassay
(2008), the oral cavity, duodenum, jejunum, and any gross lesions were
collected from each rodent and saved in 10% neutral buffered formalin for
histopathologic evaluation. Tissue sections (5 lm) were stained with
hematoxylin and eosin for microscopic examination and evaluated by
a veterinary pathologist for evaluation and diagnosis. Tissues were diagnosed
and categorized using standardized nomenclature with lesions ranked for
severity.
GSH and GSSG analyses. Reduced glutathione (GSH) and oxidized
glutathione (GSSG) parameters were measured in ﬁve animals from each
treatment group (subgroup B, Table 1). GSH and GSSG were measured in
plasma, as well as in oral mucosal tissue (from hard and soft palate) and
duodenal and proximal jejunal mucosae (scraped) on days 8 and 91. Samples
were collected, processed, and stored as previously described (Thompson et al.,
2011b). GSH and GSSG were determined ﬂuorometrically using the o-
phthalaldehyde procedure as previously described (Senft et al., 2000). The
calculation for redox potential (DE) is described in detail elsewhere (Dalton
et al., 2004) and is as follows: DE ¼  240 mV   (61.5 mV/2) 3 log([GSH]
2/
[GSSG]).
8-Isoprostane and 8-hydroxydeoxyguanosine analyses. Lipid oxidation
was measured in ﬁve animals from each treatment group (subgroup B, Table 1).
One sample of oral cavity and one sample of duodenum from each rat were
snap-frozen and stored at  80 C until homogenization. Homogenization buffer
solution was prepared as previously described (Thompson et al., 2011b).
Tissues were then homogenized in 0.3 ml using an Omni THQ homogenizer
(Omni International, Kennesaw, GA) and a disposable hard tissue tip.
After homogenization, samples were snap-frozen and stored at  80 C until
assayed. 8-Isoprostane (8-isoprostane is also known as 8-iso-prostaglandin
F2a, 8-epi-PGF2a, and 15-isoprostane F2t)
2 was analyzed via OxiSelect
8-iso-Prostaglandin F2a ELISA Kit obtained from Cell Biolabs (San Diego,
CA) and normalized to protein content via BCA assay (Pierce, Rockford, IL).
Oxidative DNA damage was measured in ﬁve animals from each treatment
group (subgroup B, Table 1); these samples were prepared as described in
Thompson et al. (2011b).
Cytokine and chemokine analyses. Cytokines and chemokines were
measured in ﬁve animals from each treatment group (subgroup B, Table 1).
One sample of oral cavity and one sample of duodenum were prepared as
described above (for 8-isoprostane). For serum collection, each animal was
anesthetized with CO2/O2, and blood samples were collected from the retro-
orbital sinus into serum separator tubes containing no anticoagulant. The
contents of the tubes were centrifuged to separate serum. The tissue and sera
samples for rats were analyzed for 22 cytokines/chemokines via a Milliplex Rat
Cytokine Kit (Millipore, Billerica, MA) on a Luminex 200 (Austin, TX). The
cytokines/chemokines included in this kit are shown in Supplementary table
S1. Cytokine levels were normalized to protein content.
Iron status. Serum iron levels were measured in 10 animals from each
treatment group (5 each from subgroups A and D, Table 1). Iron status was
evaluated in half of the animals designated for macroscopic and microscopic
pathological evaluation on day 91. Animals were anesthetized using CO2/O2,
and blood samples (~0.4 ml) were collected from the retro-orbital plexus into
tubes containing no anticoagulant. The contents of the tubes were centrifuged
to separate serum. One aliquot of serum was used for measurement of serum
iron, and another was snap-frozen and stored at  80 C for potential future
analysis. Serum iron was measured using the Cobas c501 Clinical Chemistry
Analyzer (Version 04-02; Roche Diagnostics, Indianapolis, IN). Blood
ferritin and transferrin were measured using commercial ELISA kits
purchased from ALPCO (Salem, NH). The iron content in bone marrow
smears was also assessed in the same ﬁve animals from the ‘‘Mutation
analysis’’ group (Table 1). In each animal, one bone marrow smear was
prepared and stained with Prussian blue to assess the presence of iron in
different treatment groups.
Measurement of total chromium and iron in tissues. Tissue levels of
total chromium and iron were measured in ﬁve animals (subgroup E, Table
1). Samples of the oral cavity, glandular stomach, duodenum, jejunum,
ileum, liver, plasma, and RBCs were collected for evaluation of total
chromium (Cr) and iron (Fe) content from animals exposed for 90 days.
Animals were anesthetized using CO2, and tissues were removed, ﬂushed of
contents, snap frozen, and stored at approximately  80 C. Samples were
shipped frozen to Brooks Rand Laboratories where ~100 mg of tissue was
digested in nitric acid in a controlled microwave digestion program.
Samples were then brought to a ﬁnal volume of 8 ml with deionized water.
Analysis was performed using EPA Draft Method 1638 (modiﬁed) using
inductively coupled plasma-mass spectrometry with Dynamic Reaction Cell
(DRC) technology. Digested samples were analyzed utilizing internal
standardization with rhodium. This method incorporates ionization of the
sample in an inductively coupled radio frequency plasma, with detection of
the resulting ions by mass spectrometer on the basis of their mass-to-charge
ratio. The limit of detection was 0.02 lg Cr/g tissue. Iron levels were
simultaneously measured in these tissue samples, and the limit of detection
was 0.2 lgF e / gt i s s u e .
Data management and statistical evaluation. During the in-life phase of
the study, Provantis (Version 7, Instem Life Sciences Systems, Ltd,
Staffordshire, U.K.) was used for the direct on-line capture of most in-life
and pathology data. In addition, Provantis interfaced with the Cobas c501
Clinical Chemistry Analyzer (Version 04-02, Roche Diagnostics) for capture of
serum iron data. Environmental monitoring of animal rooms (i.e., temperature/
humidity and light/dark cycles) was performed using the Edstrom Watchdog
System (Version 5.13; Edstrom Industries, Inc., Waterford, WI). The remainder
of the data was collected manually.
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were ﬁrst tested for dose-related trends using Jonckheere’s test (Jonckheere,
1954). Biochemical data sets with a signiﬁcant trend were then analyzed by
Williams’ (parametric) or Shirley’s tests (nonparametric) (Shirley, 1977),
whereas Dunnett’s (parametric) or Dunn’s (nonparametric) tests were run if
there was not a monotone trend. Water consumption and body weight data were
analyzed by one-way ANOVA followed by Dunnett’s tests. Food intake was
found to be non-normally distributed and was analyzed by Kruskall-Wallis test,
followed by Wilcoxon-Mann-Whitney test with Bonferroni adjustment.
Statistical packages used included R (http://www.R-project.org), Prism 5 for
Mac (GraphPad Software, San Diego, CA, www.graphpad.com), and
Provantis. Microscopic lesion data were analyzed by Fisher’s exact test (one-
sided) using Prism 5 for Mac.
RESULTS
Gross and Histopathological Findings
Exposure of rats to SDD for 90 days had no effect on survival,
nor were there any clinical signs of treatment-related toxicity.
The mean body weight in the 520 mg/l SDD treatment group
was generally lower than control animals (Fig. 1A), but only
signiﬁcantly on weeks 5, 6, 12, and 13. Administration of SDD
had no effect on food consumption in any treatment group.
Water consumption was signiﬁcantly lower than control animals
every week at 170 and 520 mg/l SDD and for most weeks at 60
mg/l (Fig. 1B). The average daily doses of SDD to rats at day 8
and day 91 of the study are shown in Table 2. The average daily
doses of SDD in the companion 90-day mouse study are also
provided for comparison (Thompson et al.,2 0 1 1 b ).
No treatment-related gross lesions were observed in the oral
cavity or small intestine on day 8, nor were any microscopic
lesions observed in the oral cavity. In the duodenum, villous
atrophy, apoptosis, crypt cell hyperplasia, and histiocytic
inﬁltration were observed at   170 mg/l SDD (Table 3,
Supplementary ﬁgure S1). Apoptosis and crypt cell hyperplasia
were observed at 60 mg/l, but only in one of ﬁve animals. No
microscopic lesions were observed at   4 mg/l SDD. With the
exception of histiocytic inﬁltration, similar lesions were
observed in the jejunum in the 170 and 520 mg/l treatment
groups. These results are summarized in Table 3.
Consistent with ﬁndings from a previous 13-week drinking
water study conducted by the NTP (NTP, 2007), no treatment-
related gross lesions were observed after 90 days of exposure
to SDD. Also, there were no microscopic lesions observed in
the rat oral cavity. In the duodenum, apoptosis was observed
at   60 mg/l SDD, and crypt cell hyperplasia at   170 mg/l
(Table 3). Histiocytic inﬁltration was present in almost all
animals at   60 mg/l (Supplementary fig. S2). Apoptosis,
crypt cell hyperplasia, and villous atrophy were observed in
the jejunum at concentrations as low as 4 mg/l; however, the
incidences were not statistically different from control
animals in any treatment group, and in many instances the
lesions were not observed at higher concentrations (Table 3).
In contrast, there were concentration-dependent increases in
histiocytic inﬁltration beginning at 60 mg/l. Notably,
histiocytic inﬁltration in the duodenum was the only SDD-
induced histopathological lesion previously reported in the rat
small intestine (NTP, 2007, 2008).
Cytokine and Chemokine Analyses
Histiocytic inﬁltration was observed in the rat duodenum in
the previous NTP studies (NTP, 2007, 2008)a sw e l la st h i s
current study; therefore, several cytokines and chemokines
(listed in Supplementary table S1) were measured in the
duodenum, oral mucosa, and plasma on day 91. In these tissues,
the data were not normally distributed and exhibited
FIG. 1. Weekly mean body weight (A) and water intake (B) for rats during
the 13-week study.
TABLE 2
Average Daily Dose of Ingested SDD
SDD (mg/kg)
SDD, mg/l (nominal) 0.3 4 14 60 170 520
Rat
Average daily dose (day 8) 0.06 0.8 ND 12.1 29.9 80.9
Average daily dose (day 91) 0.05 0.6 ND 8.3 20.4 58.6
Mouse
a
Average daily dose (day 8) 0.08 1.1 3.3 14.0 37.4 86.8
Average daily dose (day 91) 0.07 0.9 3.1 13.2 33.0 88.7
Note. ND, not done.
aData for mouse body weight, intake, and dose are taken from Thompson
et al. (2011b).
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exhibited signiﬁcant concentration-dependent monotone trends
in the oral mucosa. In the duodenum, only two of the examined
proteins (IL-1a and IL-4) exhibited signiﬁcant monotone trends.
IL-1a was signiﬁcantly elevated at   60 mg/l (Fig. 2A).
Interleukin-4 exhibited a signiﬁcant monotone trend that was
inversely proportional to dose (Fig. 2B); however, no treatment
groups were signiﬁcantly different from control animals. Among
the cytokines/chemokines that did not show a signiﬁcant trend,
only IL-6 had a treatment group that differed signiﬁcantly from
control, namely, the 60 mg/l SDD treatment group (Fig. 2C). In
serum, only three of the examined proteins exhibited signiﬁcant
monotone trends; none of the other cytokines/chemokines
examined were signiﬁcantly altered in any treatment group. As
shown in Figure 2D, leptin appeared to be reduced by SDD
exposure. Both IL-12p70 and IP-10 also appeared to be reduced
as a result of SDD exposure (Figs. 2E–F).
Tissue and Serum Iron Levels
Exposure to SDD was previously shown to induce mild
microcytic hypochromic anemia in rats (NTP, 2008). Therefore,
iron status was assessed after 90 days of exposure to SDD. Bone
marrow smears stained for iron content with Prussian blue
indicated lower levels in rats exposed to 170 and 520 mg/l SDD
(Table 4). Serum iron levels were signiﬁcantly decreased at  
170 mg/l (Fig. 3). Ferritin and transferrin levels exhibited no
clear treatment-related effects (Supplementary table S2).
Effects of SDD on Oxidative Status
The ratio of GSH/GSSG is a key indicator of cellular redox
status (Meister and Anderson, 1983; Moriarty-Craige and Jones,
2004; Schafer and Buettner, 2001) and was therefore measured in
several portions of the alimentary canal in order to examine
whether SDD exposure induced changes in redox status. Table 5
presents the effects of SDD on the levels of GSH and GSSG in
the rat oral, duodenal, and jejunal epithelia, as well as in the
plasma on day 8. Although statistically signiﬁcant effects were
observed for GSSG, GSH/GSSG ratio, and DE in the rat oral
mucosa at the 0.3 mg/l SDD, there were no effects at any other
concentration, as such, this effect may not be treatment related. In
both the duodenum and jejunum, there were signiﬁcant increases
in GSH at   170 mg/l and GSSG at   60 mg/l. However, there
TABLE 3
Summary of Histopathology in the Rat Duodenum and Jejunum
Pathology 0 0.3 4 60 170 520
Day 8
Duodenum
Villous atrophy –– –– –– –– 3/5
a (1), 2/5
a (2) 2/5 (1)
Apoptosis –– –– –– 1/5 (1) 3/5
a (1), 1/5
a (2) 3/5 (1)
Crypt cell hyperplasia –– –– –– 1/5 (1) 3/5
a (2), 2/5
a (3) 1/5
a (1), 4/5
a (2)
Histiocytic inﬁltration in the villous –– –– –– –– 2/5 (1), 1/5 (2) 4/5
a (1)
Jejunum
Villous atrophy –– –– –– –– 4/5
a (1) 3/5 (1)
Apoptosis –– –– –– –– 3/5 (1) 2/5 (1)
Crypt cell hyperplasia –– –– –– –– 3/5
a (1), 2/5
a (2) 2/5
a (1), 3/5
a (2)
Day 91
Duodenum
Villous atrophy –– –– –– –– 1/10 (2) ––
Apoptosis –– –– –– 3/10 (1) 3/10
a (1), 1/10
a (2) 6/10
a (1), 1/10
a (2)
Crypt cell hyperplasia –– –– –– –– 5/10
a (1) 4/10
a (1)
Histiocytic inﬁltration in the villous –– –– –– 2/10
a(1), 7/10
a(2) 1/10
a(2), 6/10
a(3), 3/10
a(4) 1/10
a(1), 1/10
a(2), 2/10
a(3),6/10
a(4)
Jejunum
Villous atrophy –– –– 1/10 (3) –– –– ––
Apoptosis –– –– 1/10 (1) –– 2/10 (1) ––
Crypt cell hyperplasia –– –– 2/10 (1) –– 3/10 (1) 1/10 (1)
Histiocytic inﬁltration in the villous –– –– –– 3/10 (1) 6/10
a (1), 1/10
a (2) 5/10
a (1), 4/10
a (2)
Note. Values in parentheses are severity scores for the lesions (1, minimal; 2, mild; 3, moderate; 4, marked). Histopathological grading—villous atrophy:
minimal ¼ < 25% decrease in villous height; mild ¼ 25 and   50% decrease in villous height; moderate ¼ 50 and   75% decrease in villous height; marked
¼ 75% decrease in villous height; apoptosis: minimal ¼ < 5 apoptotic cells per 403 or high power ﬁeld (HPF); mild ¼ approximately   5 and   10 apoptotic
cells per HPF; moderate ¼ 10 and   20 apoptotic cells per HPF; marked ¼ 20 apoptotic cells per HPF; crypt cell hyperplasia: minimal ¼ 1 and   2 times
the normal crypt depth; mild ¼ 2 and   3 times the normal crypt depth; moderate ¼ 3 and   4 times the normal crypt depth; marked ¼ 4 times the normal
crypt depth; and histiocytic inﬁltration in the villous lamina propria: minimal ¼ a few macrophages in fewer than half of the villi; mild ¼ macrophages in the villi
which were readily discernible at 103 and present in   50 and < 75% of the villi.
aSigniﬁcantly different (p   0.05) from control by Fisher’s exact test (severity scores were combined for statistical tests).
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in any treatment group. In contrast, the GSH/GSSG ratio was
signiﬁcantly decreased at 520 mg/l in the jejunum. In the plasma,
there were signiﬁcant increases in GSH (  60 mg/l), GSSG ( 
170 mg/l), and redox potential (  60 mg/l).
Changes in GSH, GSSG, and redox potential after 90 days
of exposure to SDD in drinking water are shown in Table 6.
In the oral mucosa, signiﬁcant decreases in GSH and signiﬁcant
increases in GSSG were observed at   170 mg/l SDD. Signiﬁcant
decreases in the GSH/GSSG ratio and redox potential occurred at
  60 mg/l. In the duodenum, statistically signiﬁcant increases in
GSH and GSSG occurred at   170 mg/l; however, there was no
apparent change in the GSH/GSSG ratio or redox potential. In the
jejunum, a signiﬁcant decrease in GSH, the GSH/GSSG ratio, and
redox potential (i.e., increased DE) occurred at   60 mg/l SDD,
while GSSG levels were signiﬁcantly elevated at   170 mg/l. In
the plasma, signiﬁcant increases in GSH and GSSG were
observed at   60 mg/l, and a signiﬁcant decrease in the GSH/
GSSG ratio started at 170 mg/l SDD (Table 6).
In addition to GSH and GSSG parameters, lipid oxidation and
DNA oxidation were assessed in the duodenum and oral mucosa
at day 91. Relative to controls, there were no statistically
signiﬁcant changes in 8-isoprostane, a measure of lipid oxidation,
in the duodenum or oral mucosa at any exposure concentration
(data not shown). Levels of 8-hydroxydeoxyguanosine (8-
OHdG), a measure oxidative DNA damage, were not statistically
altered in the duodenum or oral mucosa of rats at any SDD
concentration (Supplementary fig. S3).
Tissue Concentrations of Total Chromium
To better understand chromium disposition in the rat
alimentary canal, total tissue chromium (Crt) levels were
TABLE 4
Scores of Iron Content in Rat Bone Marrow Smears
SDD mg/l Moderate Moderate/slight Slight
0 4/5 1/5 0/5
0.3 5/5 0/5 0/5
4 5/5 0/5 0/5
60 4/5 1/5 0/5
170 2/5 3/5 0/5
520 0/5 0/5 5/5
Note. Scores are based on the grading scheme of Gale et al. (1963).
FIG. 2. Measures of cytokines/chemokines in the rat duodenum (A–C) and serum (D–F) on day 91. All plots (except C) were signiﬁcant for trend; *p < 0.05
compared to control group by Shirley’s test. In plot (C), statistically different from control by Dunn’s test (p < 0.05). Groups without boxes were mostly comprised
of nondetect values.
FIG. 3. Serum iron levels in rats on day 91. *p < 0.05 compared to control
by ANOVA followed by Dunnett’s test.
84 THOMPSON ET AL.measured in the oral cavity, stomach, duodenum, jejunum, and
ileum following 90 days of exposure to SDD in drinking water
(Fig. 4). With the exception of the glandular stomach and
ileum, statistically signiﬁcant increases occurred at   60 mg/l
SDD. Signiﬁcant increases in the glandular stomach and ileum
occurred at   170 mg/l and 520 mg/l, respectively. Within the
intestinal segments, the Crt levels were higher in the more
proximal portions (duodenum) than distal portions (ileum).
However, measurement of chromium in scraped samples of the
duodenum and proximal 6 cm of the jejunum indicate that
chromium levels are generally comparable between the
duodenum and proximal jejunum (Fig. 4, inset). These data
suggest that the Crt levels in the jejunum (~65 cm in length)
likely decrease in a proximal-to-distal fashion. Chromium
levels in the oral cavity, the tissue that developed tumors in rats
in the NTP 2-year bioassay (NTP, 2008), were much lower
than in the duodenum.
Comparisons of Gastrointestinal Tissue Dosimetry and
Oxidative Stress in Rats and Mice
Comparison of the Crt levels in the oral mucosae of rats and
mice indicates slightly lower tissue levels in rats on a milligram
per kilogram basis of SDD dose (Fig. 5A). It is apparent,
however, that Crt levels in the oral mucosae were higher in
mice than rats in their respective 520 mg/l SDD treatment
groups. In the small intestine, Crt levels were higher in mice
than rats within each of the three intestinal segments (Fig. 5B).
The effects of SDD on the GSH/GSSG ratios in both species
are plotted in Figure 6 on a milligram per kilogram body weight
basis for comparison. In the oral mucosae, SDD elicited
signiﬁcant decreases in the GSH/GSSG ratio in rats at
concentrations   8 mg/kg but had essentially no effect on the
GSH/GSSG ratio in mice (Fig. 6A). In the duodenum, SDD
signiﬁcantly reduced the GSH/GSSG ratio in mice at   3 mg/kg
but had no similar effect in rats (Fig. 6B). In the jejunum,
TABLE 5
Redox Values in Rat Oral and Intestinal Epithelia and Plasma on Day 8
SDD (mg/l)
GSH (nmol/mg) GSSG (nmol/mg) GSH/GSSG DE GSSG/2GSH (mV)
a
Average SEM Average SEM Average SEM Average SEM
Oral cavity
0 36.86 2.297 3.16 0.308 11.81 0.457  207.26 0.505
0.3 35.35 2.328 4.42
b 0.135 7.97
c 0.297  201.43
c 1.411
4 33.38 1.297 3.39 0.175 9.98 0.665  203.66 1.311
60 32.42 2.112 3.06 0.205 10.65 0.542  204.12 1.310
170 35.30 3.020 3.39 0.361 10.51 0.364  205.03 1.209
520 33.47 3.583 3.19 0.125 10.39 0.818  203.89 2.634
Duodenum
0 13.12 0.352 0.24 0.008 55.97 2.031  214.33 0.731
0.3 14.34 0.795 0.27 0.021 54.76 1.830  215.17 0.459
4 14.62 1.174 0.26 0.011 55.29 2.853  215.43 1.694
60 15.01 1.380 0.27
d 0.012 54.57 2.931  215.55 1.879
170 15.52
d 0.712 0.31
e 0.016 50.62 2.516  215.16 1.125
520 15.57
d 0.860 0.28
d 0.005 54.93 2.600  216.28 1.319
Jejunum
0 7.82 0.610 0.17 0.008 48.02 4.817  204.97 2.394
0.3 7.90 0.382 0.18 0.013 45.29 3.523  204.54 1.529
4 8.23 0.333 0.19 0.011 43.24 1.020  204.66 0.382
60 8.41 0.481 0.24
d 0.004 35.35 2.156  202.12 1.581
170 9.96
d 0.422 0.26
e 0.021 38.84 3.799  205.52 1.813
520 11.07
e 0.581 0.36
e 0.008 30.74
e 1.543  203.99 1.353
Plasma GSH (lM) GSSG (lM)
0 15.85 0.215 5.76 0.103 2.75 0.032  118.22 0.24
0.3 15.99 0.487 5.76 0.173 2.78 0.080  118.43 0.70
4 16.58 0.257 5.66 0.157 2.93 0.046  119.66 0.17
60 18.99
d 0.532 7.06 0.128 2.69 0.074  120.30
d 0.71
170 21.54
e 0.491 7.66
e 0.160 2.81 0.024  122.60
e 0.37
520 23.93
e 0.316 8.47
e 0.112 2.83 0.074  124.06
e 0.52
aSee ‘‘Materials and Methods’’ section for calculation.
bStatistically signiﬁcant from control by Dunn’s test (p < 0.05).
cStatistically signiﬁcant from control by Dunn’s test (p < 0.01).
dStatistically signiﬁcant from control by Shirley’s tests (p < 0.05).
eStatistically signiﬁcant from control by Shirley’s tests (p < 0.01).
TOXICITY OF Cr(VI) IN THE ALIMENTARY CANAL 85SDD reduced the GSH/GSSG ratio in both species (Fig. 6C).
GSH levels were increased in the duodenal mucosae of both
s p e c i e sa td a y9 1b u tw e r ed e c r e a s e di nt h ej e j u n a lm u c o s a e
(Fig. 7), perhaps suggesting tissue-speciﬁc differences in response
to SDD.
DISCUSSION
The purpose of this drinking water study, and the companion
study by Thompson et al. (2011b), was to investigate the
carcinogenic MOAs of Cr(VI) in the target tissue of rats and
mice by investigating possible key events that may precede
tumor formation. Consistent with the earlier NTP 90-day
drinking water study (NTP, 2007), no obvious gross lesions
were observed in any tissues of rats exposed to SDD. Likewise,
there were no histopathological lesions in the oral mucosa at
day 8 or day 91. With the exception of histiocytic inﬁltration,
many of the intestinal lesions described in Table 3 were not
previously reported. One explanation for the differences in
histopathology is that the water intake in this current study,
while consistent with published intake values (U.S. EPA,
1988), was higher than in the NTP studies (NTP, 2007, 2008).
For example, the mean water consumption in the 520 mg/l
group at 13 weeks in this study was 15.5 g/day, whereas the
values for female rats in the 500 mg/l group at 13 weeks in the
NTP 90-day study was 9.1 g/day, and 8.4 g/day in the 516 mg/l
group in the NTP 2-year bioassay (NTP, 2007, 2008). The
reason for these differences is unclear, but the data imply that
the mg/kg body weight doses in the current study were higher
than in the NTP study at comparable milligram per liter SDD
concentrations.
The histopathological ﬁndings in the rat small intestine were
generally similar to those reported for mice (Thompson et al.,
2011b), with one notable exception. In mice, cytoplasmic
vacuolization was observed at both day 8 and day 91 starting
at 170 and 60 mg/l SDD, respectively. At both time points,
vacuolization occurred at lower SDD concentrations than villous
TABLE 6
Redox Values in Rat Oral and Intestinal Epithelia and Plasma on Day 91
GSH (nmol/mg) GSSG (nmol/mg) GSH/GSSG DE GSSG/2GSH (mV)
a
SDD (mg/l) Average SEM Average SEM Average SEM Average SEM
Oral cavity
0 38.30 0.973 3.04 0.126 12.66 0.383  208.80 0.497
0.3 39.22 0.992 2.93 0.110 13.43 0.266  209.92 0.351
4 36.30 1.006 2.97 0.124 12.28 0.501  207.65 0.743
60 34.42 1.403 3.64 0.241 9.64
b 0.796  203.55
b 1.487
170 31.17
b 2.032 3.82
b 0.253 8.36
c 0.915  200.11
c 2.255
520 28.23
c 1.336 3.70
b 0.103 7.67
c 0.503  197.89
c 1.569
Duodenum
0 18.90 1.058 0.25 0.011 75.08 4.620  223.00 1.461
0.3 17.60 0.592 0.24 0.005 72.59 2.461  221.72 0.886
4 18.50 0.844 0.25 0.017 75.06 5.518  222.69 1.409
60 20.51 0.757 0.29 0.017 71.13 4.092  223.43 0.976
170 22.73
b 1.129 0.33
b 0.013 70.27 5.631  224.53 1.632
520 25.15
c 0.933 0.38
c 0.020 67.31 5.019  225.35 1.385
Jejunum
0 16.43 0.858 0.30 0.011 54.64 3.469  216.87 1.560
0.3 16.14 0.556 0.30 0.021 55.31 4.830  216.75 1.582
4 14.61 0.395 0.33 0.016 44.48 2.795  212.63 1.061
60 13.43
b 0.731 0.35 0.012 38.19
b 1.599  209.46
b 1.235
170 11.53
c 0.515 0.45
c 0.032 26.09
c 1.992  202.25
c 1.425
520 10.82
c 0.796 0.48
c 0.022 22.32
c 0.891  199.35
c 1.416
Plasma GSH (lM) GSSG (lM)
0 32.27 1.950 4.12 0.141 7.85 0.434  141.53 1.52
0.3 31.45 0.892 3.90 0.191 8.15 0.443  141.76 1.06
4 35.85 1.475 4.81 0.151 7.46 0.299  142.35 1.01
60 44.75
b 1.505 7.09
b 0.469 6.38 0.292  143.22 0.60
170 50.81
c 1.946 9.20
c 0.642 5.70
b 0.626  143.15 1.88
520 52.09
c 2.470 14.10
c 0.730 3.75
c 0.315  137.99 1.76
aSee ‘‘Materials and Methods’’ section for calculation.
bStatistically signiﬁcant from control by Shirley’s tests (p < 0.05).
cStatistically signiﬁcant from control by Shirley’s tests (p < 0.01).
86 THOMPSON ET AL.atrophy and crypt cell hyperplasia. Vacuolization can be a sign
of injury and thus suggests that damage to the villous epithelium
resulted in crypt epithelial hyperplasia in mice. There are many
potential causes of vacuolization including altered lipid metab-
olism, sequestration of absorbed material, autophagy, endoplas-
mic reticulum stress, and proteasome dysfunction (Franco and
Cidlowski, 2009; Henics and Wheatley, 1999; Mimnaugh et al.,
2006). The apparent difference in treatment-related vacuolization
in rats and mice may indicate subtle (but important) differences
in response to Cr(VI) in the two species.
Cr(VI) readily reacts with reductants such as GSH and
ascorbate, which can generate intermediate chromium species,
reactive oxygen species, and changes in redox status (Zhitkovich,
2005). Table 7 provides a comparison of the redox effects of
Cr(VI) in target tissues of rats and mice at day 91 with the tumor
outcomes reported in the NTP 2-year bioassay (NTP, 2008). For
all tissues that developed tumors in the 2-year bioassay, oxidative
stress was present at day 91. In the oral mucosae, oxidative stress
and tumors occurred in rats but not mice, despite the fact that oral
mucosae Crt levels were slightly higher in mice.
Comparison of the effects in the duodenum of both species
also suggests involvement of oxidative stress (Table 7).
Tumors were only observed in the mouse duodenum in NTP
(2008), and oxidative stress was apparent only in the duodenal
epithelium of mice at day 91. It is apparent, however, that GSH
and GSSG levels increased in the rat duodenum as a function
of dose (Table 6)—suggesting that an adaptive response may
have prevented signiﬁcant changes in the GSH/GSSG ratio or
the GSSG/2GSH redox potential (i.e., DE). Although lesions
were observed in the rat duodenum at day 91 in the absence of
oxidative stress, this observation might simply reﬂect that at the
time of euthanasia, the cells had adapted to oxidative stress but
that the tissue was still undergoing repair. In this regard, the
incidences for atrophy and crypt hyperplasia at day 91 were
lower than day 8 (Table 3, Supplementary ﬁg. S4)—implying
that the lesions might have resolved if the study duration
were longer, which would be consistent with the negative
tumor ﬁndings in the 2-year bioassay (NTP, 2008). Notably,
the mg/kg SDD dose decreased in rats with increased
duration (Table 2).
In the jejunum, oxidative stress was again observed in
a tissue that developed tumors; however, it was also present in
the rat jejunum, which did not develop tumors (Table 7). As
was observed in the duodenum, the incidences for atrophy and
crypt hyperplasia at day 91 were lower or even absent when
compared with day 8 (Table 3, Supplementary ﬁg. S4), and
thus these tissues may have recovered if the study duration
were longer. Notably, the apparent discrepancy in redox status
and histopathology in the jejunum might be explained by the
anatomical location of the analyses. Jejunal redox measures
were taken from the proximal 6 cm, whereas histopathology
was assessed about midway through the jejunum (i.e., at ~32 cm).
Dosimetry data herein suggest that Crt levels decrease distally
within the intestinal tract; thus, redox changes in the mid
portion of the jejunum (where histopathology was assessed)
were likely milder than in the proximal jejunum. Given the
higher water intake in this study relative to the NTP studies, it
cannot be ruled out that the proximal jejunum of rats in this
current study would have experienced prolonged oxidative
stress and injury if the study had continued.
FIG. 4. Concentration of total Cr (Crt) in the rat alimentary canal on day
91. Data plotted are mean and SEM. *, Signiﬁcantly different from control by
Shirley’s test (p < 0.05); #, Signiﬁcantly different from control by Shirley’s test
(p < 0.01). The inset shows a comparison of Cr in scraped epithelial cells from
the duodenum (D) and proximal 6 cm of the jejunum (J) in the 60 and 520 mg/l
SDD treatment groups. Data represent mean and SEM. **, Signiﬁcantly
different by t-test.
FIG. 5. Concentration of total Cr (Crt) in the oral (A) and intestinal mucosae (B) of rats and mice on day 91. The two highest SDD drinking water
concentrations are shown in (A) for reference. Duo, duodenum; Jej, jejunum; and Ile, ileum.
TOXICITY OF Cr(VI) IN THE ALIMENTARY CANAL 87Taken together, this study and that by Thompson et al.
(2011b) suggest that the rodent duodenum and jejunum respond
differently to SDD. Within each species, the chromium levels in
scraped duodenal and proximal jejunal samples were similar, yet
the redox responses differed. In both species, oxidative stress
was more severe in the proximal jejunum than duodenum. In
rats, SDD did not signiﬁcantly alter the GSH/GSSG ratio or
redox potential in the duodenum but signiﬁcantly decreased both
parameters in the jejunum. In mice, SDD signiﬁcantly decreased
the GSH/GSSG ratio in the duodenum and jejunum but
only signiﬁcantly decreased redox potential in the jejunum
(Thompson et al.,2 0 1 1 b ). In both species, GSH levels increased
in the duodenum and decreased in the jejunum as a function of
SDD (Fig. 7). Interestingly, previous studies using consecutive
10-cm sections of the rat small intestine indicated that duodenal
segments could reduce oxidants infused into the lumen more
efﬁciently than jejunal segments via release of cysteine (Dahm
and Jones, 2000). These data suggest that the duodenum and
jejunum regulate oxidative stress differently and underscore the
importance of understanding both dosimetry and MOA in
predicting the toxicity of ingested Cr(VI).
Despite signs of oxidative stress in the rat oral mucosa and
mouse duodenum, no increases in 8-isoprostane or 8-OHdG were
observed in either species. Possible explanations for these
negative ﬁndings are that the assays lacked sufﬁcient sensitivity
to detect changes or that repeated exposure to SDD resulted in
the induction of homeostatic processes. Considering that
oxidative stress and inﬂammation are interrelated (Kruidenier
and Verspaget, 2002; Rahman and MacNee, 2000; Roberts et al.,
2009) and that histiocytic inﬁltration was observed in the small
intestines of rats and mice (NTP, 2007, 2008; Stout et al., 2009),
we expected to see increased cytokine levels in both species
following SDD exposure (Thompson et al.,2 0 1 1 a ). Contrary to
expectations, duodenal levels of the pro-inﬂammatory cytokines
IL-1b and TNFa were decreased in mice (Thompson et al.,
2011b). In contrast to mice, the pro-inﬂammatory cytokine IL-1a
was elevated in the rat duodenum. Interestingly, the proteasome
is required for pro-inﬂammatory signaling, and proteasome
inhibitors are anti-inﬂammatory and can induce vacuolization
(Elliott et al., 2003; Mimnaugh et al.,2 0 0 6 ; Neurath et al., 1998;
Reinstein, 2004). Whether the differences in vacuolization in the
two species relate to differences in cytokine signaling is
unknown; however, toxicogenomic data from the animals in
these studies are expected to provide additional information
regarding immune and oxidative responses.
Previous SDD drinking water studies have indicated anemic
effects in both species, with greater severity in rats (NTP, 2007,
2008; Stout et al., 2009). Similar ﬁndings were observed in this
current study and our companion study in mice (Thompson
et al., 2011b); speciﬁcally, iron levels in serum and bone
smears were lower in rats. In regard to the speciﬁcity of SDD-
induced oral tumors in rats, iron deﬁciency has been linked to
the etiology of oral cavity cancers (Lucenteforte et al., 2009;
Prime et al., 1983; Richie et al., 2008). For example, Prime
FIG. 6. Measures of GSH/GSSG ratios in the oral mucosa (A), duodenum
(B), and jejunum (C) of rats and mice on day 91. Data for rats are from Tables 5
and 6, whereas data for mice are from Thompson et al. (2011b). *, Statistically
different from respective control group by Shirley’s test.
FIG. 7. Effects of SDD on intestinal GSH levels in rats and mice at day 91.
88 THOMPSON ET AL.et al. (1983) reported that anemia increases the risk of oral
cancer in rats. In humans, Richie et al. (2008) reported that
mild iron deﬁciency and low GSH levels increased the risk of
oral cavity cancer. Lucenteforte et al. (2009) evaluated data
from 46 human studies investigating the risk of oral and
pharyngeal cancer and reported possible associations between
iron deﬁciency and excess oral cancer risk.
Mechanistic explanations for the association between anemia
and oral cancers are unknown. However, chromium can
compete with iron for Hb and transferrin binding (Ani and
Moshtaghie, 1992; Gray and Sterling, 1950; Hopkins and
Schwarz, 1964); such competition could result in a reduction in
the rate of iron-consuming pathways, including Hb synthesis,
and the consequent appearance of anemia. Chromium might
also alter protein function via cofactor competition. For
example, Cr(VI) has been hypothesized to deplete ascorbate
levels, thereby decreasing the ascorbate-dependent activity of
the histone demethylase JHDM2A (Sun et al.,2 0 0 9 ).
Similarly, iron-dependent histone demethylases can be
inhibited via competition with nickel ions (Chen et al., 2006,
2010). Thus, oxidative stress, iron depletion and/or competi-
tion, and depletion of reductants like GSH and ascorbate might
alter critical enzymes involved in DNA structure and repair.
In summary, the data herein, together with that in Thompson
et al. (2011b), support that oxidative stress may be a key event
in the MOA for Cr(VI)-induced carcinogenesis. Additional
analyses currently underway with tissues collected from the rat
and mouse 90-day studies should further inform the key events
in the MOAs. Moreover, the pharmacokinetic data collected in
these studies will improve our understanding of the species
difference in Cr(VI) disposition and will be used to develop
physiologically based pharmacokinetic models for extrapola-
tion between species and from the very high concentrations of
Cr(VI) that cause cancer in rodents to environmentally relevant
human exposures.
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